Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor

• Published in: Antimicrobial agents and chemotherapy 2015-01, Vol.59 (1), p.331-337
• Main Authors: Nayar, Asha S, Dougherty, Thomas J, Reck, Folkert, Thresher, Jason, Gao, Ning, Shapiro, Adam B, Ehmann, David E
• Format: Article
• Language: English
• Subjects: Bacterial Proteins - genetics; DNA Gyrase - genetics; Drug Resistance, Bacterial; Drug Resistance, Bacterial - drug effects; Drug Resistance, Bacterial - genetics; Escherichia coli; Escherichia coli - drug effects; Escherichia coli - genetics; Escherichia coli Proteins - genetics; Mechanisms of Resistance; Microbial Sensitivity Tests; Morpholines; Morpholines - pharmacology; Mutation; Naphthyridines; Naphthyridines - pharmacology; Pseudomonas aeruginosa; Pseudomonas aeruginosa - drug effects; Pseudomonas aeruginosa - genetics; Topoisomerase II Inhibitors; Topoisomerase II Inhibitors - pharmacology
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.04077-14

In a previous report (T. J. Dougherty, A. Nayar, J. V. Newman, S. Hopkins, G. G. Stone, M. Johnstone, A. B. Shapiro, M. Cronin, F. Reck, and D. E. Ehmann, Antimicrob Agents Chemother 58:2657-2664, 2014), a novel bacterial type II topoisomerase inhibitor, NBTI 5463, with activity against Gram-negative pathogens was described. First-step resistance mutations in Pseudomonas aeruginosa arose exclusively in the nfxB gene, a regulator of the MexCD-OprJ efflux pump system. The present report describes further resistance studies with NBTI 5463 in both Pseudomonas aeruginosa and Escherichia coli. Second-step mutations in P. aeruginosa arose at aspartate 82 of the gyrase A subunit and led to 4- to 8-fold increases in the MIC over those seen in the parental strain with a first-step nfxB efflux mutation. A third-step mutant showed additional GyrA changes, with no changes in topoisomerase IV. Despite repeated efforts, resistance mutations could not be selected in E. coli. Genetic introduction of the Asp82 mutations observed in P. aeruginosa did not significantly increase the NBTI MIC in E. coli. However, with the aspartate 82 mutation present, it was possible to select second-step mutations in topoisomerase IV that did lead to MIC increases of 16- and 128-fold. As with the gyrase aspartate 82 mutation, the mutations in topoisomerase IV did not by themselves raise the NBTI MIC in E. coli. Only the presence of mutations in both targets of E. coli led to an increase in NBTI MIC values. This represents a demonstration of the value of balanced dual-target activity in mitigating resistance development.